Show simple item record

dc.contributor.authorGertz, Morie A.
dc.contributor.authorRué i Monné, Montserrat
dc.contributor.authorBlood, Emily
dc.contributor.authorKaminer, Lynne S.
dc.contributor.authorVesole, David H.
dc.contributor.authorGreipp, Philip R.
dc.date.accessioned2016-05-19T09:48:22Z
dc.date.issued2004
dc.identifier.issn1042-8194
dc.identifier.urihttp://hdl.handle.net/10459.1/57059
dc.description.abstractWaldenström macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma that strongly expresses CD20 on the cell surface. This study was undertaken to determine the response rate of patients with untreated or previously treated WM to the monoclonal antibody rituximab, which is directed against CD20+ expressed by B-cell lymphomas. Thirty-four untreated and thirty-five previously treated patients received rituximab 375 mg/m2 weekly for 4 consecutive weeks by intravenous infusion on days 1, 8, 15, and 22. Sixty-nine patients were evaluable for response; 19 (27.5%) achieved an objective response and 17 (24.6%) achieved a minor response. The overall response rate was 52.2% (90% CI [41.6%, 62.6%]). Of previously untreated patients 35.3% vs. 20% of previously treated patients achieved an objective response. Median response duration was not significantly different between previously untreated (27 months) and previously treated patients (not reached, P = 0.8). Rituximab produced objective or minor responses in 52.2% of patients and is an active agent in the treatment of WM. Grade 4 toxicity was seen in 11%.ca_ES
dc.language.isoengca_ES
dc.publisherTaylor & Francisca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1080/10428190410001714043ca_ES
dc.relation.ispartofLeukemia & Lymphoma, 2004, vol. 45, núm. 10, p. 2047-2055ca_ES
dc.rights(c) Taylor & Francis Ltd., 2004ca_ES
dc.subjectLymphoplasmacytic lymphomaca_ES
dc.subjectMonoclonal IgM proteinca_ES
dc.subjectRituximabca_ES
dc.subjectWaldenström macroglobulinemiaca_ES
dc.titleMulticenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)ca_ES
dc.typearticleca_ES
dc.identifier.idgrec009163
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_ES
dc.identifier.doihttps://doi.org/10.1080/10428190410001714043
dc.date.embargoEndDate2025-01-01


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record